We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eloxx Pharmaceuticals Inc | NASDAQ:ELOX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.82 | 3.60 | 3.75 | 0 | 01:00:00 |
| | |
Per Share
|
| |
Per Pre-Funded
Warrant Underlying Share |
| |
Total
|
| |||||||||
Offering price
|
| | | $ | 5.255 | | | | | $ | 5.254 | | | | | $ | 1,999,925.45 | | |
Placement agent fees(1)
|
| | | $ | 0.3941 | | | | | $ | 0.3941 | | | | | $ | 150,000.03 | | |
Proceeds to us, before expenses
|
| | | $ | 4.8609 | | | | | $ | 4.8599 | | | | | $ | 1,849,925.42 | | |
| | | | | S-ii | | | |
| | | | | S-1 | | | |
| | | | | S-3 | | | |
| | | | | S-5 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-11 | | | |
| | | | | S-12 | | | |
| | | | | S-13 | | | |
| | | | | S-15 | | | |
| | | | | S-17 | | | |
| | | | | S-19 | | | |
| | | | | S-19 | | | |
| | | | | S-20 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 20 | | | |
| | | | | 24 | | | |
| | | | | 26 | | | |
| | | | | 26 | | |
|
Offering price per share of common stock
|
| | | | | | | | | $ | 5.255 | | |
|
Net tangible book value per share as of June 30, 2023
|
| | | $ | (7.46) | | | | | | | | |
|
Increase in net tangible book value per share attributable to new investors purchasing shares and Pre-Funded Warrants in this offering
|
| | | | 1.57 | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | | (5.89) | | |
|
Dilution per share to new investors participating in this offering
|
| | | | | | | | | $ | 11.14 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 20 | | | |
| | | | | 24 | | | |
| | | | | 26 | | | |
| | | | | 26 | | |
1 Year Eloxx Pharmaceuticals Chart |
1 Month Eloxx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions